Table 3 Top canonical pathways
Affected eyes of AAU patients versus eyes of healthy controls | Affected versus unaffected eye of AAU patients | Affected eyes of bacterial keratitis patients versus eyes of healthy controls | Affected versus unaffected eyes of bacterial keratitis patients | ||||
|---|---|---|---|---|---|---|---|
Name | P-value | Name | P-value | Name | P-value | Name | P-value |
Acute phase response signaling | 1.07E-26 | LXR/RXR activation | 2.80E-28 | LXR/RXR activation | 6.85E-25 | LXR/RXR activation | 3.20E-29 |
LXR/RXR activation | 6.50E-26 | FXR/RXR activation | 8.72E-28 | FXR/RXR activation | 1.84E-24 | FXR/RXR activation | 1.05E-28 |
FXR/RXR activation | 1.9E-25 | Acute phase response signaling | 1.11E-27 | Acute phase response signaling | 7.90E-21 | Acute phase response signaling | 2.05E-28 |
Clathrin-mediated endocytosis signaling | 3.97E-12 | Coagulation system | 5.86E-13 | Glucocorticoid receptor signaling | 1.69E-11 | Coagulation system | 9.63E-13 |
Atherosclerosis signaling | 4.51E-11 | Glucocorticoid receptor signaling | 5.61E-11 | Glycolysis I | 2.86E-11 | Glucocorticoid receptor signaling | 3.99E-11 |